|drug3103||Serology for Covid-19 Wiki||1.00|
|drug2966||SARS-CoV-2 rS/Matrix-M1 Adjuvant Wiki||1.00|
|D008173||Lung Diseases, Obstructive NIH||0.28|
|D008171||Lung Diseases, NIH||0.22|
|D011024||Pneumonia, Viral NIH||0.12|
There is one clinical trial.
Molecular testing (e.g PCR) of respiratory tract samples is the recommended method for the identification and laboratory confirmation of COVID-19 cases. Recent evidence reported that the diagnostic accuracy of many of the available RT-PCR tests for detecting SARS-CoV2 may be lower than optimal. Of course, the economical and clinical implications of diagnostic errors are of foremost significance and in case of infectious outbreaks, namely pandemics, the repercussions are amplified. False positives and false-negative results may jeopardize the health of a single patient and may affect the efficacy of containment of the outbreak and of public health policies. In particular, false-negative results contribute to the ongoing of the infection causing further spread of the virus within the community, masking also other potentially infected people.
Description: assess if inpatients who presented with pneumonia but had a negative test for Covid-19 are positive at the serology for SARS-CoV-2.Measure: Serology Time: 3 weeks
Description: to find if the combination of CT scan and serology could help us in the identification of those patients who were initially negative at laboratory testing alone.Measure: Efficacy of CT scan and Serology Time: 3 weeks
Description: the efficacy of different pharmaceutical treatments against Covid-19Measure: Efficacy of different pharmaceutical treatments Time: 3 weeks
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports